Scienmag

JUNE 2, 2022

An investigation into the evolution of Salmonella bacteria infecting Brazilian poultry shows that the introduction of a Salmonella vaccine, combined with increasing antibiotic usage by Brazilian farmers, has led to the rise of strains that are more antibiotic-resistant, but less likely to cause disease in humans.

Bacteria 78

Bacteria Vaccination Vaccine 78

Bio Pharma Dive

JULY 27, 2023

The pharma said its latest shot, which covers 21 strains of bacteria, cleared two Phase 3 trials and in some cases spurred a stronger immune response than Pfizer’s Prevnar 20.

Immune Response 245

Immune Response Bacteria Vaccination Vaccine 245

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 9, 2022

When babies in the African countries of Guinea Bissau and Uganda were given the tuberculosis vaccine, something remarkable happened.

Vaccination 195

Vaccination Vaccine Bacteria Research 195

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Vaccination Vaccine 75

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccination 81

Vaccination Vaccine Immune Response Bacteria 81

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

Scienmag

MAY 9, 2021

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

Bacteria 49

Bacteria Vaccination Vaccine Research 49

Pharmaceutical Technology

DECEMBER 21, 2023

This innovative composition induces a protective immune response against Group A Streptococcus (GAS) bacteria, offering potential targets for vaccine development. Discover a groundbreaking immunogenic composition patent that combines GAS polypeptide antigens and polypeptide-polysaccharide conjugates.

Immune Response 100

Immune Response Bacteria Vaccination Vaccine 100

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

Drug Discovery World

MARCH 27, 2024

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. billion people estimated to be infected with the bacteria, according to the World Health Organization (WHO). TB remains a global pandemic, with 1.8

Vaccination 52

Vaccination Vaccine Bacteria Clinical Trials 52

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […]. UNIVERSITY PARK, Pa.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Drug Discovery World

NOVEMBER 4, 2022

New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. infection in infants who became infected with the bacteria but did not progress to active TB. Most individuals infected with M.tb

Vaccination 52

Vaccination Vaccine Development Bacteria 52

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). anthracis , primarily affecting livestock and wild game.

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

Scienmag

JULY 8, 2021

A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases Credit: Wyss Institute at Harvard University.

Vaccination 98

Vaccination Vaccine Bacteria Drugs 98

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 117

Vaccination Vaccine Bacterium Protein 117

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

NPR Health - Shots

NOVEMBER 9, 2022

Several crises in the country — including political instability, COVID and financial collapse — have created deteriorating conditions that have allowed the bacteria to spread. Image credit: Ari Daniel/NPR)

Bacteria 98

Bacteria Vaccination Vaccine 98

Drug Discovery World

FEBRUARY 22, 2023

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding. The Strep A bacteria causes strep throat and scarlet fever and is a major driver of antibiotic use in children.

Vaccination 52

Vaccination Vaccine Research Bacteria 52

XTalks

AUGUST 17, 2022

August is National Immunization Awareness Month (NIAM), which is marked to help raise awareness about the importance of vaccines in the protection of public health. One of the themes of this year’s National Immunization Awareness Month is “vaccines work.” Vaccination Awareness from the FDA.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Scienmag

JUNE 10, 2022

Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies.

Antibody 72

Antibody Bacteria Bacterium Vaccination 72

pharmaphorum

SEPTEMBER 28, 2021

Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.

Vaccination 100

Vaccination Vaccine Bacteria Protein 100

Drug Discovery World

APRIL 26, 2024

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Bacteria 52

Medical Xpress

DECEMBER 23, 2022

Formed in response to infection and vaccination, these microscopic training grounds allow B cells to perfect the antibodies they deploy against specific viruses and bacteria.

Bacteria 105

Bacteria Antibody Manufacturing Vaccination 105

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . VLA15 is the only Lyme disease vaccine candidate currently in clinical development. Valneva Pfizer Report Positive Phase 2 Pediatric Data for Lyme Vaccine Candidate.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

Drug Discovery World

APRIL 24, 2023

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. There is currently no vaccine available. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

Pfizer

FEBRUARY 16, 2023

who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. OspA is a surface protein expressed by the bacteria when present in a tick.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The post GSK bolsters vaccines division with $3.3bn swoop on Affinivax appeared first on. GlaxoSmithKline has agreed a $3.3

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

Drug Discovery World

JULY 28, 2023

It means the resulting medication will be less likely to have existing resistance in the bacteria and potentially it will take longer for resistance to develop,” Professor Blaskovich said. million deaths globally in 2019 were directly attributed to resistant bacteria and a further 4.9 million deaths were associated.

Bacteria 97

Bacteria Doctors Doctor Development 97

Drug Discovery World

APRIL 14, 2023

Perhaps most significantly, Ghana accepted the R21/Matrix-M malaria vaccine for use in children, Moderna revealed that cancer vaccines could be ready by 2030, and a new treatment for long Covid fatigue could be available soon.

Drugs 52

Drugs Bacteria Vaccination Vaccine 52

Drug Discovery World

MARCH 17, 2023

New discovery could help prevent secondary breast cancer Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours.

Bacteria 52

Bacteria Drugs Scientist Vaccination 52